NASDAQ : AZTA

Azenta, Inc.

$27.16 USD

$0.57 (2.14%)

Volume
482.03K
Average Volume
1.07M
Market Capitalization
$1.25B
P/E Ratio
-6.88
Dividend Yield
0.00%
Price Target
$45.00
Year High
$41.73
Year Low
$15.93
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$2.83
Company Overview

NASDAQ

John Marotta

Medical - Instruments & Supplies

Healthcare

AZTA

2900

US

USD

https://www.azenta.com

978 262 2626

114340102

0000933974

Liquidity Metrics

0.04

2.83

2.52

0.91

0.00

Sales & Valuation

$593.82M

2.10

0.80

43.59

0.62

Profitability

-$1.22

-$55.76M

-29.86%

-25.09%

-10.69%

-9.36%

P/E Metrics

-6.88

0.05

0.05

Analyst Price Target & Rating

$45.00

$45.00

$45.00

Sell

2/5

12 Analysts

-39.64%

Financial Health Scores

3.35

3/9

$469.79M

$1.9B

$349.21M

-$149.67M

Key Metrics (TTM)

$1.03B

1.73

-11.12

2.83

-10.69%

-0.70%

-14.72%

2.37%

130 days

Company Executives
Name Title
John Marotta President, Chief Executive Officer & Director
Lawrence Y. Lin Executive Vice President & Chief Financial Officer
Ginger Zhou Advisor
Alex Esmon Vice President and General Manager of Sample Repository Solutions
William E. Martin Senior Vice President & President of Multiomics
Michael Paulo Vice President, Chief Information & Digital Officer
Olga Pirogova Senior Vice President & Chief HR Officer
Andrea O'Hara Strategic Technical Specialist of Azenta Life Sciences
Yvonne Perron Vice President of Financial Planning & Analysis and Investor Relations
Ephraim Starr Senior Vice President, General Counsel & Corporate Secretary
Poll Results

No votes yet today — be the first to share your view!

About Azenta, Inc. (NASDAQ:AZTA) Stock

Azenta, Inc. is a global leader specializing in advanced solutions for the discovery, handling, and preservation of life science samples. The company's operations span across North America, Europe, Asia Pacific (including China), and other international markets. Its business is structured into two main reportable segments: Life Sciences Products and Life Sciences Services. The Life Sciences Products division supplies sophisticated automated systems for the cold storage of chemical compounds and biological specimens. This segment also provides crucial equipment for sample preparation and manipulation, along with various consumables and specialized instruments that empower customers to effectively manage samples throughout their entire research and development workflows. Conversely, the Life ... Sciences Services segment offers a comprehensive suite of programs for sample management, integrated cold chain logistics, cutting-edge informatics, and a range of sample-centric laboratory services. These offerings are vital for propelling scientific research and accelerating drug development. Key services include secure sample banking, advanced genomic sequencing, gene synthesis, laboratory processing, detailed laboratory analysis, biospecimen acquisition, and other essential support functions. Azenta caters to a diverse client base within the life sciences sector, encompassing pharmaceutical companies, biotechnology firms, biorepositories, and academic or private research institutions. Established in 1978, the company, originally known as Brooks Automation, Inc., officially became Azenta, Inc. in December 2021. Its corporate headquarters are located in Chelmsford, Massachusetts.

Azenta Announces Fiscal 2026 Third Quarter Conference Call and Webcast

2026-07-22 16:05:00

BURLINGTON, Mass., July 22, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) will announce fiscal third quarter 2026 earnings which ended on June 30, 2026, on Tuesday, August 4, 2026, after the market closes.

Azenta Completes Sale of B Medical Systems

2026-07-08 08:00:00

BURLINGTON, Mass., July 8, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced the completion of the previously disclosed sale of its B Medical Systems business to Thelema S.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Azenta, Inc. - AZTA

2026-06-04 10:00:00

NEW YORK, June 4, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Azenta, Inc. ("Azenta" or the "Company") (NASDAQ: AZTA).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Azenta, Inc. - AZTA

2026-06-02 17:19:00

NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Azenta, Inc. (“Azenta” or the “Company”) (NASDAQ: AZTA).  Such investors are advised to contact Danielle Peyton at [email protected]  or 646-581-9980, ext. 7980.

Azenta Inc (AZTA) Stock Up 5.4% and Still Undervalued -- GF Score: 72/100

2026-05-28 21:19:00

On May 28, 2026, Azenta Inc (AZTA) shares rose 5.4%, bringing the current price to $22.49. The stock has experienced considerable volatility, with a 52-week ran

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Azenta, Inc. - AZTA

2026-05-28 10:00:00

NEW YORK, May 28, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Azenta, Inc. ("Azenta" or the "Company") (NASDAQ: AZTA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Azenta, Inc. (AZTA) Securities Fraud Investigation - Levi & Korsinsky

2026-05-27 09:00:00

Azenta, Inc. reaffirmed 3%-5% organic revenue growth and 300 basis points of margin expansion in February 2026 -- then cut both targets three months later after recording a $149 million goodwill impairment. NEW YORK, May 27, 2026 /PRNewswire/ -- Shareholders who purchased Azenta, Inc. (NASDAQ: AZTA) stock lost significant value after the Company slashed its FY 2026 guidance on May 5, 2026 -- reversing projections it had publicly reaffirmed just three months earlier.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Azenta, Inc. - AZTA

2026-05-26 17:39:00

NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Azenta, Inc. (“Azenta” or the “Company”) (NASDAQ: AZTA). Such investors are advised to contact Danielle Peyton at  [email protected]  or 646-581-9980, ext. 7980.

Frequently Asked Questions

What is the current Azenta, Inc. (AZTA) stock price?

Azenta, Inc.(NASDAQ:AZTA) stock price is $27.16 in the last trading session. During the trading session, AZTA stock reached the peak price of $41.73 while $15.93 was the lowest point it dropped to. The percentage change in AZTA stock occurred in the recent session was 2.14% while the dollar amount for the price change in AZTA stock was $0.57.

AZTA's industry and sector of operation?

The NASDAQ listed AZTA is part of Medical - Instruments & Supplies industry that operates in the broader Healthcare sector.

Who are the executives of AZTA?

John Marotta | President, Chief Executive Officer & Director
Lawrence Y. Lin | Executive Vice President & Chief Financial Officer
Ginger Zhou | Advisor
Alex Esmon | Vice President and General Manager of Sample Repository Solutions
William E. Martin | Senior Vice President & President of Multiomics

How many employees does AZTA have?

Number of AZTA employees currently stands at 2900. AZTA operates from 200 Summit Drive, Burlington, MA 01824, US.

Link for AZTA official website?

Official Website of AZTA is: https://www.azenta.com

How do I contact AZTA?

AZTA could be contacted at phone #978 262 2626 and can also be accessed through its website. AZTA operates from 200 Summit Drive, Burlington, MA 01824, US.

How many shares of AZTA are traded daily?

The average number of AZTA shares traded daily for last 3 months was 1.07M.

What is the market cap of AZTA currently?

The market value of AZTA currently stands at $1.25B with its latest stock price at $27.16